Skip to main content

Treatment Clinical Trials for Myelodysplastic Syndrome

Review the myelodysplastic syndrome treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 151-175 of 217

A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)
Status: Active
Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York
Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Patients with High-Risk Acute Leukemia or Myelodysplastic Syndrome
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Ruxolitinib with or without Abatacept for the Prevention of Graft Versus Host Disease and Cytokine Release Syndrome after T-cell Haploidentical Stem Cell Transplant in Patients with Hematologic Malignancies
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Status: Active
Location: 2 locations
Rezatapopt in Combination with Azacitidine with or without Venetoclax for the Treatment of TP53Y220C Mutant Relapsed, Refractory or Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Eltanexor and Venetoclax for the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
CPX-351 With or Without Venetoclax in Treating Patients with Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Q702 with Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
HC-7366 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome/Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
8-Chloroadenosine in Combination with Decitabine and Venetoclax for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Study of APVO436 in Patients With AML or MDS
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
CER-1236 in Patients With Acute Myeloid Leukemia (AML)
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Infusion of Conventional and Regulatory T-Cells for the Treatment of Patients with Hematologic Malignancies Undergoing Reduced Intensity Donor Stem Cell Transplant
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
GTB-3650 TriKE® for the Treatment of Patients with High Risk Myelodysplastic Syndromes and Refractory/Relapsed Acute Myeloid Leukemia
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody with Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients with High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
TCRαβ+ and CD19+ Depleted Donor Lymphocyte Infusion after Donor Stem Cell Transplant for the Prevention of Relapse in Patients with High-Risk Blood Cancers
Status: Active
Location: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin
Donor Blood Stem Cells (Ex Vivo TCR Alpha/Beta and CD19-Depleted Stem Cells) for the Prevention of Graft-versus-Host Disease in Pediatric Patients with Blood Cancer
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
CD45RA Depleted T Cell Infusion after Alpha/Beta Depleted Stem Cell Transplant for the Reduction of Complications in Patients at Risk for Viral or Fungal Infections
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
CD123-Directed Autologous or Donor Derived T-Cell Therapy for the Treatment of Relapsed or Refractory Acute Myelogenous Leukemia, CATCH-AML Study
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee